n.a. (TKMR)

4.02
0.08 1.95
NASDAQ
Prev Close 4.10
Open 4.22
Day Low/High 3.98 / 4.33
52 Wk Low/High 4.01 / 26.73
Volume 346.21K
Exchange NASDAQ
P/E Ratio N/A
Div & Yield N.A. (N.A)
Tekmira Presents New Anti-Viral Efficacy Data Against The Marburg Hemorrhagic Fever Virus

Tekmira Presents New Anti-Viral Efficacy Data Against The Marburg Hemorrhagic Fever Virus

Studies Achieved 100% Protection Against Most Deadly Strain of Marburg Virus When Dosed 24 Hours After Lethal Exposure Levels in Non-Human Primates Using RNAi Therapeutic Developed by Tekmira and Its Collaborators

Tekmira Provides Update On Licensed Product Candidate, Marqibo(R)

Tekmira Provides Update On Licensed Product Candidate, Marqibo(R)

Spectrum Pharmaceuticals Launches Marqibo and Ships First Commercial Orders

Tekmira Provides Corporate Update And Announces Second Quarter 2013 Results

Tekmira Provides Corporate Update And Announces Second Quarter 2013 Results

Conference Call at 4:30 pm Eastern Time Today

Tekmira Initiates TKM-PLK1 Phase I/II Clinical Trial, Enrolling Patients With Advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) Or Adrenocortical Carcinoma (ACC)

Tekmira Initiates TKM-PLK1 Phase I/II Clinical Trial, Enrolling Patients With Advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) Or Adrenocortical Carcinoma (ACC)

Future Clinical Development Plans Outlined for Tekmira's Oncology Therapeutic, TKM-PLK1

Tekmira Provides Update On Licensed Product Candidate, Marqibo(R)

Tekmira Provides Update On Licensed Product Candidate, Marqibo(R)

Spectrum Pharmaceuticals Acquires Talon Therapeutics and Guides for Launch of Marqibo Later This Year

Tekmira Presents LNP Technology Innovations At Scientific Symposium

Tekmira Presents LNP Technology Innovations At Scientific Symposium

Highlights Include Advancements in LNP Potency, Lyophilization, and Subcutaneous Administration

Tekmira Provides Corporate Update And Announces First Quarter 2013 Results

Tekmira Provides Corporate Update And Announces First Quarter 2013 Results

Conference Call at 4:00 pm Eastern Time Today

Tekmira Provides Update On U.S. Government Sponsored TKM-Ebola Program

Tekmira Provides Update On U.S. Government Sponsored TKM-Ebola Program

Scope and Funding of Contract Expanded to Include New, More Potent LNP Formulation

Tekmira's Collaborators At The National Cancer Institute Present Preclinical Data At The Annual Meeting Of The American Association For Cancer Research (AACR)

Tekmira's Collaborators At The National Cancer Institute Present Preclinical Data At The Annual Meeting Of The American Association For Cancer Research (AACR)

Researchers Examine LNP-Enabled WEE1-CSN5 siRNA Combination Therapeutic Against Liver Cancer

Tekmira Provides Corporate Update And Announces Year-End Audited 2012 Results

Tekmira Provides Corporate Update And Announces Year-End Audited 2012 Results

Conference Call at 4:30 pm Eastern Time Today

5 Stocks Under $10 Triggering Breakouts

5 Stocks Under $10 Triggering Breakouts

These under-$10 stocks look poised to trade higher from current levels.

Tekmira Outlines Key 2013 Product Development And Corporate Milestones

Tekmira Outlines Key 2013 Product Development And Corporate Milestones

Company Presentation to be Webcast at BIO CEO Conference at 10:30 am ET

Tekmira's LNP Technology Highlighted In Peer-Reviewed Publication, Cancer Discovery

Tekmira's LNP Technology Highlighted In Peer-Reviewed Publication, Cancer Discovery

Results Outline Most Comprehensive Human Experience to Date for RNAi Therapeutics Delivered With Lipid Nanoparticles (LNPs)

3 Pharma Stocks Leaping on Unusual Volume

3 Pharma Stocks Leaping on Unusual Volume

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility.

Tekmira Provides Periodic Update To Shareholders Regarding Litigation

Tekmira Provides Periodic Update To Shareholders Regarding Litigation

Patent Infringement Suit Proceeds to Answer of Filed Complaints